rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

SkinHealth Systems Inc.

SKIN · Nasdaq

Health CareMedical DevicesNot moving yet

SKIN stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 29.8% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
94 (-17)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$21K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders94-17 on the quarter
New · exited17 · 35
Reported value$46.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Capricorn Fund Managers Ltdadded · filed 24 Jul 202622,276,935$15.4M+2,872,743+14.8%
FMR LLCreduced · filed 13 Aug 202610,201,685$7.1M-6,981,546−40.6%
BlackRock, Inc.added · filed 7 Aug 20268,516,203$5.9M+1,158,589+15.7%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20267,536,938$5.2M+1,819,478+31.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,496,485$2.4M+55,477+1.6%
Woodline Partners LPreduced · filed 14 Aug 20262,328,700$1.6M-3,370,284−59.1%
Silver Point Capital L.P.unchanged · filed 17 Aug 20261,592,030$1.1M00.0%
D. E. Shaw & Co., Inc.reduced · filed 14 Aug 20261,432,312$992K-466,163−24.6%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026960,374$665K-1,281,222−57.2%
UBS Group AGadded · filed 13 Aug 2026839,383$582K+599,031+249.2%
31 Mar 2023 – 30 Jun 2026
87104120Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Pedro Bruno Ferreira Malha Company insiderPresident and CEO · last 9 Oct 20260 · 0
Michael P. Monahan Company insiderChief Financial Officer · last 10 Aug 20261 · 0
Sheri Lewis Company insiderCSO and COO · last 9 Apr 20260 · 0
Ronald Menezes Company insiderChief Revenue Officer · last 20 Mar 20260 · 0
Philippe Schaison Company insiderDirector · last 13 Nov 20250 · 0
Brent L. Saunders Company insiderDirector, Other · last 16 Jun 20252 · 0
Brian Christopher Miller Company insiderDirector · last 16 Jun 20251 · 0
Desiree Gruber Company insiderDirector · last 16 Jun 20250 · 1
Doug K. Schillinger Company insiderDirector · last 16 Jun 20251 · 0
Michelle C. Kerrick Company insiderDirector · last 16 Jun 20250 · 0
Stephen J. Fanning Company insiderDirector · last 16 Jun 20250 · 0
Marla Malcolm Beck Company insiderPresident and CEO · last 9 Apr 20250 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202565.3%
Operating profit marginFY 2025 · to 31 Dec 2025-6.9%
Free cash flow marginFY 2025 · to 31 Dec 202512.4%
Return on capital employedFY 2025 · to 31 Dec 2025-6.6%
Research spendFY 2025 · to 31 Dec 20251.9%
Share count trendFY 2025 · to 9 Mar 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$232.7M
Free cash flowFY 2025 · to 31 Dec 2025$37.2M

Analyst forecasts

No analyst forecasts yet.